Stock Market Today, Feb: ImmunityBio Up on Anktiva EU OK
ImmunityBio sails higher after the EU green lights ANKTIVA for bladder cancer, igniting waves across biotech stocks. ...
Why Active Funds May Underperform Benchmarks discusses persistent headwinds, costs, and timing issues that hinder outperformance.
26,804 articlesImmunityBio sails higher after the EU green lights ANKTIVA for bladder cancer, igniting waves across biotech stocks. ...
The 30-year fixed rate slipped below 6% for the first time since 2022, sparking renewed hope for homebuyers and those...
Trump rejects Kurdish involvement in Iran war, triggering cautious moves in oil, equities, and currencies as markets ...
AI-driven demand and easing supply bottlenecks push chipmakers into the spotlight. Here’s a timely look at the best s...
IonQ has surged nearly 200% over five years as quantum computing gains attention. This guide breaks down whether late...
When a member of a royal family steps into the public eye after a major news cycle, personal finances can feel the pr...
A prominent corporate treasury revealed it may begin selling Bitcoin to raise dollars and reduce debt, ending a long-...
Platform-scale brokerages are redefining how buyer leads are allocated and how loans are funded. The shift, powered b...
Ares Capital has long dazzled income investors with a high dividend yield. After a challenging quarter, the question ...
Mel Robbins, the millionaire podcaster, pushes back against the Gen Z lazy stereotype, arguing that today’s young wor...
AI-driven models are outlining a bold bitcoin price prediction: reach $1 million for BTC by 2035, supported by ETF in...
A mid-career executive carved tax savings from a $480,000 severance by spreading payments across two years, illustrat...